Major Depressive Disorder

Latest News

Fava Beans, Dopamine, Depression, and Parkinson Disease

July 10th 2025

Fava beans emerge as a powerful natural source of L-DOPA, offering potential benefits for mood disorders and Parkinson's disease and holding enriching culinary traditions.

Transformation 2.0: The GLP-1 RAs as Psychiatric Medications?

By Roger S. McIntyre, MD, FRCPC

July 7th 2025

Scientists Find Cellular Brain Changes Tied to PTSD

By Isabella Backman

July 1st 2025

Positive Results From the Phase 2b Study of BPL-003 in Patients With Treatment-Resistant Depression

By Leah Kuntz

July 1st 2025

Mount Sinai Researchers Uncover a Promising New Way to Modulate Brain Cell Activity to Potentially Treat Major Depressive Disorder in Adults

By Elizabeth Dowling

June 30th 2025

Latest CME Events & Activities

Southern California Psychiatry Conference

July 11-12, 2025

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Southern Florida Psychiatry Conference

November 21-22, 2025

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

More News

Diagnosis and Treatment of Bipolar Disorder in Children and Adolescents

Mary Beth Cogan

May 1st 1996

Since 1980, criteria for diagnosing bipolar disorder in adults have also been used to diagnose mania in children, with some modifications to adjust for age.

Scientists Study Serotonin Markers for Suicide Prevention

Leslie Knowlton

September 1st 1995

Brain serotonin levels as a predictor of suicide has been the subject of intense research scrutiny over the past several years, with scientists trying to find easily accessible markers so that the neurotransmitter's levels might someday be readily measured in clinical settings.

Venlafaxine in the Treatment of Depression: Practical Considerations

Charles Debattista, MD

January 1st 1995

Venlafaxine (Effexor) is a novel antidepressant recently released to the American market. Its entry into the antidepressant market has been much heralded. The lay press has described the drug as "Prozac with a punch," and many patients were asking for it long before it was available. As the hoopla settles down, we are learning that venlafaxine is a potentially important drug with both advantages and disadvantages over other available antidepressants, including the selective serotonin reuptake inhibitors (SSRIs).

...

50 51 52 53 54